U.S. Markets close in 4 hrs 39 mins

Vestas Wind Systems A/S (VWS.CO)

Copenhagen - Copenhagen Real Time Price. Currency in DKK
Add to watchlist
611.00-16.00 (-2.55%)
At close: 4:59PM CEST
Full screen
Previous Close627.00
Open626.00
Bid611.00 x
Ask611.50 x
Day's Range604.00 - 627.50
52 Week Range392.30 - 632.50
Volume1,582,419
Avg. Volume777,308
Market Cap129.84B
Beta0.67
PE Ratio (TTM)107.04
EPS (TTM)5.71
Earnings DateAug 17, 2017
Dividend & Yield1.38 (1.46%)
Ex-Dividend Date2017-04-07
1y Target Est610.39
  • Reuters28 days ago

    Kenya says major wind power line to be ready in three months

    A power line linking a 310 megawatt (MW) wind power plant to Kenya's national grid, delayed by landowners' compensation demands among other issues, is expected to be ready in the next three months, the energy minister said on Thursday. Kenya relies heavily on geothermal and hydro power for its electricity, providing the bulk of the country's total 2,341 MW output. Wind power provides about 25 MW.

  • Reuters2 months ago

    Lack of power lines hits sub-Saharan Africa's biggest wind farm

    The biggest wind farm in sub-Saharan Africa is ready for launch but will remain idle until next year as Kenya's government has not yet installed the transmission lines needed to get the clean power to customers, the provider of the turbines said. Danish wind turbine maker Vestas Wind Systems installed 365 turbines at Lake Turkana in the hot desert north of the east African country in March, completing construction in less than a year and two months ahead of schedule.

  • Reuters2 months ago

    European stocks fall as investors flee risk, drugmaker Roche weighs

    European shares extended their fall on Tuesday, with healthcare stocks particularly weak, as a diplomatic spat in the Middle East weakened appetite for risky assets across the board. The greatest downward pull came from healthcare stocks. Swiss heavyweight drugmaker Roche fell 5.5 percent, its biggest one-day drop in 30 months, after investors were disappointed by findings in its Aphinity study for a key breast cancer treatment.